Biotech's recovery isn't a 'head fake.'  These 3 stocks could lead the next leg up

Biotech is described as an out-of-favor sector even as industry fundamentals improve, with investors focused on three stocks trading near multiyear lows. The article frames current positioning as cautious/risk-off toward the group despite improving underlying fundamentals.

Analysis

Biotech is described as an out-of-favor sector even as industry fundamentals improve, with investors focused on three stocks trading near multiyear lows. The article frames current positioning as cautious/risk-off toward the group despite improving underlying fundamentals.